$NVO

Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today

This article details the stocks making significant moves in Tuesday's midday trading. Novo Nordisk (NVO) is up after FDA approval for its Wegovy pill, Trinity Biotech (TRIB) rose on a large order for its HIV diagnostic test, and VisionWave (VWAV) increased due to a new patent. Conversely, Starfighters Space (FJET) experienced a drop after a massive rally, and ServiceNow (NOW) fell following its acquisition of a cybersecurity startup.

Original reporting
Stocktwits · Rounak Jain
Published Dec 23, 2025, 5:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Dec 23, 2025, 6:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today — source image
Decision brief

The 30-second read

$NVOBullishMed
01

Why it matters

These developments suggest a positive short-term outlook for selected biotech and tech stocks, with some caution advised due to market volatility.

02

Market read

The news impacts biotech and technology sectors with potential short-term trading opportunities, especially in companies with recent approvals or patent grants.

03

What to watch

Potential regulatory hurdles or competitive responses could dampen positive catalysts; macroeconomic factors may influence overall market sentiment.

Timing: Immediate to short-term (next 1-3 days)

Background

The article summarizes significant stock movements driven by recent corporate news and approvals, highlighting sector-specific catalysts.

Company-level read

Ticker impact

$NVOBullishHigh confidence
Context

Significant positive movement following FDA approval for Wegovy.

Expected impact

Expected short-term price increase of approximately 3-5%.

Evidence & confidence

FDA approval is a strong fundamental catalyst, likely to sustain investor optimism in the near term.

$TRIBBullishMedium confidence
Context

Stock rose on a large order for HIV diagnostic tests.

Expected impact

Potential for a 2-4% rise in stock price over the next few days.

Evidence & confidence

Order volume indicates strong demand, but stock movement may be tempered by broader market conditions.

$VWAVBullishMedium confidence
Context

Increased due to a new patent, indicating potential for competitive advantage.

Expected impact

Likely to see a modest rise of 1-3% in the short term.

Evidence & confidence

Patent grants can provide a competitive edge, but actual market impact depends on execution and industry response.

$FJETBearishMedium confidence
Context

Experienced a drop after a rally, indicating possible profit-taking or correction.

Expected impact

Potential for a 2-4% decrease in the near term.

Evidence & confidence

Profit-taking after rally is common; technical indicators should be monitored for support levels.

$NOWBearishMedium confidence
Context

Fell following acquisition of cybersecurity startup.

Expected impact

Expected to remain volatile; short-term downward bias of 1-3%.

Evidence & confidence

Acquisition news can be a double-edged sword; market reaction depends on perceived strategic value.

Market effects

Positive momentum in life sciences and technology sectors due to FDA approval and patent grants.

Primarily US-focused, with potential ripple effects in global biotech and tech markets.

Moderate; specific to biotech, diagnostics, and tech sectors with international players.

Counterpoint

Market reaction to FDA approval and patents may be already priced in; subsequent gains could be limited.

Key entities

  • Novo Nordisk

    A global healthcare company specializing in diabetes care and other biopharmaceuticals.

  • Trinity Biotech

    A biotech firm focusing on diagnostic tests and medical devices.

  • VisionWave

    A technology company holding a new patent related to its product portfolio.

  • Starfighters Space

    A space technology firm that experienced a recent rally and subsequent correction.

  • ServiceNow

    A cloud computing company providing digital workflow solutions.

Related articles

$LLYHighAI 9/10

Eli Lilly stock jumps as GLP-1 sales widen Novo lead

Eli Lilly shares rose up to 7% after Q2 revenue jumped 48% to $22.97B, beating Wall Street by over $2B. Mounjaro and Zepbound totaled $14.87B, about 65% of revenue. Lilly lifted its 2026 outlook to $85B-$87B. Novo Nordisk also raised guidance, but U.S.-listed shares fell after Wegovy pill sales missed expectations.

$NVOMed

A promising heart drug fails, challenging a long-held theory of disease

Novo Nordisk’s Zeus trial of ziltivekimab in 6,300+ patients with heart disease or advanced kidney disease reduced inflammation biomarkers IL-6 and CRP, but did not lower cardiovascular events or deaths. Novo said it will continue two other ziltivekimab studies, ending in 2027. The results challenge the inflammation hypothesis for atherosclerosis.

$NVOMed

Why Is Everyone Talking About Novo Nordisk?

Novo Nordisk (NVO) fell about 13% over a week after a phase 3 trial setback for ziltivekimab, an investigational drug, missing its primary endpoint. The company reported Q2 revenue up 2% to 78.5 billion DKK and adjusted EPS of 6.18 DKK. Wegovy oral pill sales slightly missed expectations. Fiscal 2026 adjusted sales guidance was revised slightly higher.

$NVOMed

Germany first EU country to launch Wegovy oral GLP-1

Novo Nordisk said Germany will be the first EU country to roll out Wegovy oral semaglutide, after the European Commission granted marketing authorization in July. The launch is scheduled for September, with more EU availability expected in 2H 2026. In a 64-week trial, pill users lost about 33 lb vs 6 lb on placebo.

$DDOGMed

Software stocks sink, led by declines from Figma, Datadog

Software stocks fell Thursday after quarterly results from Datadog, Figma, and HubSpot. Datadog shares dropped more than 15% despite beating revenue and earnings; adjusted gross margin was 80% versus 80.7% consensus. Figma also fell after warning of higher AI inference spending. iShares Expanded Tech-Software ETF (IGV) fell over 2%.